
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA is poised for a positive outlook due to the promising results from its Phase 3 clinical trials of obefazimod, which demonstrated significant efficacy and improved safety/tolerability in treating moderately to severely active ulcerative colitis. The company has raised its peak sales estimates and penetration rates, reflecting increased confidence in obefazimod’s multi-billion-dollar commercial potential in a market characterized by high unmet needs. Furthermore, the drug's rapid therapeutic effect in patients with previous treatment failures enhances its appeal, positioning Abivax favorably within the biotechnology sector.
Bears say
Abivax SA's stock outlook is negatively impacted by the inability to demonstrate compelling maintenance efficacy for its drug candidate, obefazimod, following promising initial induction results, mirroring the setbacks encountered by other therapies in the same space. Furthermore, the company's history of ongoing financial losses and lack of profitability compounds concerns about its commercial viability, especially given the precedent of prior oral therapies that have failed due to efficacy and safety issues. Additionally, uncertainties regarding the company's ability to secure favorable partnerships for commercial launch further exacerbate the risks associated with its clinical positioning within the competitive market for ulcerative colitis treatments.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares